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SUSTAINED RELEASE OF TOPICAL 
ANESTHETICS 
This application claims priority to co-pending U.S. appli-
cation Ser. No. 61/721,567 filed Nov. 2, 2012 which is 
expressly incorporated by reference herein in its entirety. 
The discomfort and irritation of the oral mucosa that an 
orthodontic patient experiences during treatment is caused by 
friction between the oral mucosa and the orthodontic brack-
ets. Administering painkillers or applying a commercially 
available non-medicated orthodontic wax over the brackets 
are options for orthodontic patients. However, orthodontic 
wax simply prevents friction and avoids further irritation, but 
does not reduce discomfort. 
Commercially available non-medicated waxes for use in 
orthodontics include, e.g., GUM® Orthodontic Wax. Com-
mercially available medicated products contain, for the most 
part, 20% benzocaine. "Dent's Extra Strength Toothache 
Gum" (Grandpa Brands, Erlanger, KY) is advertised as a 
medicated wax to place in an exposed tooth cavity or as a 
protective cover for a chipped tooth. It contains benzocaine 
20%, beeswax, petrolatum, cotton, flavor, FD&C Red No. 40 
AI. Lk. However, hypersensitivity reactions to beeswax have 
been reported, and beeswax and petrolatum are insoluble in 
water. There was a voluntary product recall (May 2012) due 
to excessive benzocaine levels in some lots. 
10 
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The disclosed method and composition is an orthodontic 
wax matrix that provides sustained release of an analgesic/ 
anesthetic agent, also termed "active", that is used in to alle-
viate oral mucosal discomfort, with the analgesic/anesthetic 
agent present in the matrix at a concentration that is relatively 
lower compared to known formulations. In one embodiment, 
the analgesic/anesthetic agent is benzocaine, which is the 
ethyl ester of para-aminobenzoic acid (PABA). In one 
embodiment, benzocaine is present in the matrix at a concen-
tration from 0.1% up to less than 15%. In one embodiment, 35 
the disclosed method and composition is an orthodontic wax 
that contains an analgesic/anesthetic agent at a concentration 
lower than that previously used, and at least one excipient that 
provides sustained release of the analgesic/anesthetic agent 
from the wax matrix over at least eight hours. The composi- 40 
tion is applied to an orthodontic bracket or brace of an orth-
odontic patient to relieve discomfort up to 24 hours. 
BRIEF DESCRIPTION OF THE DRAWINGS 
2 
this formulation additionally contains microcrystalline wax 
(Koster Keunen), glyceryl monosterate, heavy mineral oil, 
PEG 1500, and Tween 80. 
Tables 1A and 1B show exemplary formulations. 
TABLE 1A 
Ingredients Weighting % 
Microcrystalline wax 21 83 
Glyceryl monosterate 0.67 2.7 
Heavy mineral oil 0.25 1.0 
PEG 1500 1.25 5.0 
Benzocaine 1.25 5.0 
Tween 80 0.083 0.3 
Xanthumgum 0.75 3.0 
TABLE 1B 
%used in 
artificial 
saliva in 
vivo release 
Ingredients Weighting evaluation %Range 
Microcrystalline wax 21 83 50-99 
Glyceryl monosterate 0.67 2.7 0-10 
Heavy mineral oil 0.25 1.0 0-30 
PEG 1500 1.25 5.0 0-30 
Anesthetic/ analgesic 1.25 5.0 0.01-14.99 
Tween 80 0.083 0.3 0-10 
(Polysorbate 80) 
Xanthumgum 0.75 3.0 0-30 
As shown above, in embodiments, excipients are added to 
improve product characteristics. In general, in the above for-
mulation of anesthetic/analgesic agent, the microcrystalline 
wax provides a matrix; glyceryl monostearate has known 
properties as an emollient, solubilizing agent, stabilizing and 
sustained-release ingredient; heavy mineral oil has known 
properties as an emollient, lubricant, and oleaginous vehicle 
making the wax softer and less rigid; polyethylene glycol-
1500 (PEG 1500) enhances matrix hydrophilicity; Tween 80 
(Polysorbate 80) serves as a wetting/dispersing/suspending 
agent in lipophilic bases; and xanthum gum is a stabilizing 
agent and suspending agent, as described in the Handbook of 
Pharmaceutical Excipients (7'h Edition, London: Pharmaceu-
tical Press, 2012), the relevant sections of which are expressly 
FIG. 1 illustrates a calibration curve for the optical mea-
surement of varying concentrations of benzocaine in an arti-
ficial saliva simulant by absorbance spectroscopy at 284 nm. 
45 incorporated by reference herein in their entirety. 
FIG. 2 illustrates the time release of benzocaine from an 
exemplary composition into an artificial saliva simulant, as 
determined by measurements using absorbance spectroscopy 50 
at284 nm. 
The following Instruments were used in evaluations: Met-
tler AE 200 weighing balance, 4802 UVNis double beam 
spectrophotometer, and Hanson Vision Elite 8 dissolution 
apparatus 
Microcrystalline wax was melted in a beaker placed in a 
water bath maintained at 90° C. Once melted, glyceryl 
mono stearate was added, followed by 250 f.LL heavy mineral 
oil with mechanical stirring. At about the same time, PEG 
1500 was melted in another beaker placed in a water bath 
FIG. 3 illustrates an exemplary composition applied to an 
orthodontic bracket or brace affixed to a tooth of a patient. 
DETAILED DESCRIPTION 
As used herein, all percentage concentrations are weight/ 
weight. As used herein, all concentration ranges are inclusive 
in that the upper and lower values are included within the 
range, and in that all sub-ranges within the range are encom-
passed. For example, and by way of illustration only, a range 
of 0%-10% concentration of a component includes the 
absence of that component (0% ), and every concentration up 
to and including 10% (e.g., 0.01%-10%, 0.1%-10%, 0.2%-
10%,0.1%-9.9%, 0.1%-9.8, and so on). 
55 maintained at 90° C. and stirred using a magnetic stirrer at 80 
rpm. Benzocaine was added in portions every 2.5 min over a 
period of 12.5 min waiting for each addition to solubilize 
before adding the next. Tween 80 was added with continuous 
stirring and heat. Xanthum gum was then added in 0.25 g 
quantities over a period of two min while increasing stirring 
60 to 150 rpm. The wax mixture was poured into the PEG-drug 
mixture over two to three min while stirring at 200 rpm and 
stirred for an additional five min. The two mixtures were 
stirred mechanically with visual inspection. As soon as the 
wax began to solidifY, the mixture was poured in a mold. 
In one embodiment, the formation contains xanthun gum 65 
as a sustained release agent, and benzocaine (each from Spec-
trum) as the analgesic/anesthetic agent. In one embodiment, 
The formulation of Table 1A was assessed for an in vitro 
benzocaine release profile from the wax using an artificial 
saliva formulation that was prepared according to Table 2. 
US 9,387,190 B2 
3 
TABLE2 
Artificial saliva formulation 
Components Quantity (mM) 
KH2P04 2.5 
Na2HP04 2.4 
KHC03 15 
NaCl 10 
MgC12 1.5 
4 
The results of in vitro release of 5% benzocaine, formu-
lated as shown in Table 1A, in the artificial saliva formulation 
from Table 2 are reported in Table 4 and shown in FIG. 2. 
TABLE4 
Time release profile of benzocaine into artificial saliva formulation 
Time %Drug %Drug %Drug Avg% Drug Std 
(min) Released Released Released Released Deviation 
CaC12 1.5 10 -----------------------------------------
citric acid 0.15 
pH adjusted to 6. 7 with dilute HCI 
The in vitro analgesic/anesthetic release study used the 
artificial saliva formulation containing potassium phosphate 15 
monobasic (KH2 P04 ), sodium phosphate dibasic 
(Na2 HP04 ), potassium bicarbonate (KHC03 ), sodium chlo-
ride (NaCI), magnesium chloride hexahydrate 
(MgC12 .6H20), calcium chloride (CaC12), citric acid anhy-
drous, dilute hydrochloric acid (NCI), methanol, and MilliQ 20 filtered water (resistivity=18.0 megaohms). Each ingredient 
was dissolved in 150-200 mL MilliQ filtered water and 
poured in a 4 L volumetric flask placed on a stirrer (350 
RPM). KH2P04 , Na2HP04 and MgC12 were ground before 
weighing. The final pH of the solution was adjusted to 6.7 
using dilute HCI. 25 
A standard curve of benzocaine was prepared. One mg 
benzocaine was dissolved in 20 mL methanol to make a stock 
solution. The stock solution was used to make 5 mL of 
0 4.87 5.10 4.39 4.79 0.36 
30 8.31 10.91 9.07 9.43 1.34 
60 9.93 14.05 10.03 11.34 2.35 
120 14.52 19.85 15.38 16.59 2.86 
180 16.53 23.20 16.62 18.78 3.82 
240 21.59 26.93 22.74 23.76 2.81 
300 29.53 30.87 28.76 29.72 1.06 
360 40.43 38.14 40.81 39.79 1.44 
420 48.74 46.60 49.51 48.28 1.51 
480 55.91 54.66 57.35 55.97 1.34 
As the data show, this formulation had an average of 56% 
percent benzocaine released into the artificial saliva medium 
after eight hours. This release rate was more than twice that 
obtained for a previous first-generation formulation 
described in U.S. Pat. No. 6,074,674 (the '674 patent) which 
is expressly incorporated by reference herein in its entirety. 
The '674 patent formulation was 7.1% tragacanth, 70.9% 
microcrystalline wax, 2.0% Span 80, and 20.0% benzocaine. 
The '674 patent formulation had an in vitro release of only 
22.7% benzocaine released into the medium after eight hours. 
This difference was unexpected. Without being limited to a 
specific theory, and with all other variables being equal, 
Pick's Law of Diffusion would predict a greater release of 
analgesic/anesthetic agent from a matrix that contains a 
higher concentration of the analgesic/anesthetic agent. From 
increasing concentrations ofbenzocaine in artificial saliva (5 
f.LM, 10 f.LM, 15 f.LM, 20 f.LM, 25 f.LM, 30 f.LM, 35 f.LM, 40 f.LM, 45 30 
f.LM, 50 f.LM, 55 f.LM, and 60 f.LM). Absorbance of each concen-
tration was measured at 284 nm using a UV Nis double beam 
spectrophotometer. The cuvette was washed 3-4 times with 
water between each measurement. Each measurement was 
performed in triplicate, with the average absorbance of each 
concentration used to generate the standard curve. 
35 the results shown herein, however, a greater percent of ben-
zocaine was released from the disclosed formulation that 
A Hanson Vision Elite 8 dissolution apparatus was used for 
the in vitro benzocaine release study. Degassed artificial 
saliva was the dissolution medium (900 mL). The paddle 
speed was 50 rpm and the water bath was maintained at 3 7° C. 40 
Five mL of medium was withdrawn at each time point (0 min, 
contained a relatively lower benzocaine concentration, com-
pared to that in the '674 patent. Specifically, the analgesic/ 
anesthetic agent that was released from the formulation now 
disclosed was 11.3% at 1 hr, 16.6% at 2 hr, 18.8% at 3 hr, 
23.8% at 4 hr, 29.7% at 5 hr, 39.8% at 6 hr, 48.3% at 7 hr, and 
56.0% at 8 hr. The analgesic/anesthetic is released in one 
embodiment up to 24 h. 
30 min, 60 min, 120 min, 180 min, 240 min, 300 min, 360 
min, 420 min, 480 min, and 77 hours) and replaced by an 
equal volume of warm artificial saliva. Sinkers were used to 
place about 150 mg benzocaine wax in each basket. 
The results of a standard benzocaine curve prepared in 
artificial saliva are reported in Table 3 and shown in FIG. 1. 
In embodiments using a sustained release agent, xanthum 
45 gum provided both a good release rate and a good product 
aesthetic appearance. Without being bound by a specific 
theory, this may be due to the structure of the xanthum gum 
TABLE3 
Standard absorbance curve for benzocaine in artificial saliva formulation 
Avg Cone 
of Avg 
Cone Cone Cone Benzocaine Absorbance 
(fJM) (fJM) (f!M) (f!M) Absorbance Absorbance Absorbance at 284nm 
1.05 1.02 1.05 1.04 O.G18 0.011 0.013 0.014 
2.55 2.48 2.55 2.53 0.051 0.04 0.048 0.046 
5.23 5.08 5.23 5.18 0.101 0.08 0.097 0.093 
10.33 10.04 10.33 10.23 0.206 0.159 0.19 0.185 
15.43 15.00 15.43 15.29 0.325 0.243 0.307 0.292 
20.59 20.02 20.59 20.40 0.421 0.314 0.407 0.381 
25.69 24.98 25.69 25.46 0.528 0.396 0.479 0.468 
30.79 29.94 30.79 30.51 0.616 0.489 0.577 0.561 
35.83 34.83 35.83 35.50 0.740 0.585 0.724 0.683 
40.99 39.85 40.99 40.61 0.849 0.684 0.816 0.783 
46.03 44.75 46.03 45.60 0.921 0.708 0.91 0.846 
51.06 49.64 51.06 50.59 1.105 0.833 1.021 0.986 
US 9,387,190 B2 
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compound, its hydrophilic characteristic, and its emulsifying 
property that may facilitate saliva penetration of the wax 
matrix and release of the analgesic/ anesthetic. Xanthum gum 
6 
refined wax, white wax, white beeswax, yellow wax, yellow 
beeswax. In one embodiment, the wax is microcrystalline 
wax. 
is used in oral and topical pharmaceutical formulations, cos-
metics, and foods as a suspending agent, stabilizing agent, 
thickening agent, and emulsifying agent. It is nontoxic, com-
patible with most other pharmaceutical ingredients, and has 
good stability and viscosity properties over a wide pH and 
temperature range. It has been used to prepare sustained-
release matrix tablets. Such properties are known, as dis- 10 
closed in the following references, each of which is expressly 
incorporated by reference herein in its entirety: Jansson P E, 
KenneL, Lindberg B. Structure of extracellular polysaccha-
ride from Xanthamonas campestris. Carbohydr Res 197 5; 45: 
275-282; Melton L D, Mindt L, Rees D A, Sanderson GR. 15 
Covalent structure of the polysaccharide from Xanthamonas 
campestris: evidence from partial hydrolysis studies. Carbo-
hydr Res 1976; 46: 245-257; Dhopeshwarkar V, Zatz J L. 
Evaluation of xanthan gum in the preparation of sustained 
release matrix tablets. Drug Dev Ind Pharm 1993; 19: 999- 20 
1017. 
In one embodiment, a non-ionic polymer is selected from 
the group consisting of sodium carboxymethyl cellulose, 
CARBOPOL® ETD 2001 resin, tragacanth, poly(ethylene 
oxide), methylcellulose, hydroxy-propylmethylcellulose, 
karya gum, cellulose, soluble starch, gelatin, poly( vinyl pyr-
rolidone ), poly (ethylene glycol) 8000, poly( ethylene glycol) 
4000, poly( vinyl alcohol), and combinations thereof. In one 
embodiment, the non-ionic polymer is PEG 1500. 
In one embodiment, the surfactant is selected from the 
group consisting of sorbitan monolaurate, polysorbate 80, 
Spans, Tweens, and combinations thereof. In one embodi-
ment, the surfactant is polysorbate 80 (Tween 80). 
In one embodiment, the formulation contains one or more 
swelling agents, emulsifiers, surfactants, and/or wetting 
agents, each described in the Handbook of Pharmaceutical 
Excipients. These may be included to optimize or otherwise 
alter the release of active, e.g., benzocaine, from the wax 
matrix, e.g., alginic acid (also known as E400, KELACID™, 
Compared to the '67 4 patent formulation containing a rela-
tively higher 15%-25% concentration of analgesic/anes-
thetic, the formulations disclosed herein have a lower con-
centration of analgesic/anesthetic agent. This results in 
enhanced patient safety and ease of regulatory approval, 
while also providing an enhanced release profile for increased 
efficacy. The formulations disclosed herein have an improved 
aesthetic appearance, facilitating patient use and compliance, 
and are more similar to uumedicated waxes, and less similar 
to the tragacanth-containing wax described in the '67 4 patent 
with a yellow appearance. The increased percentage of the 
wax matrix assists in retaining a wax-like character; suffi-
ciently flexible to be broken off of a wax strip and applied to 
an orthodontic bracket without crumbling or falling apart, as 
shown in FIG. 3. This increases both patient acceptability, as 
well as formulation retention on orthodontic brackets. In use, 
the wax is applied to the bracket. It will then be in contact with 
the mucosa as the gums lay against the teeth. Without the wax, 
the mucosa lays against the metal bracket; this is the source of 
irritation to the mucosa. The wax will stay on the metal 
bracket because the wax is malleable. The wax will be molded 
onto the part of the bracket that protrudes and is in contact 
with the mucosa. 
L-gulo-D-marmoglycuronan, polymannuronic acid, PROT-
ACID®, SATIALGINE H8®); bentonite (also known as 
ABAGEL®, E558, MAGNABRITE®, mineral soap, 
25 POLARGEL®, soap clay, taylorite, VEEGUM® HS, wil-
kinite); calcium alginate (also known as alginic acid calcium 
salt, Algin, CA33, calc align, calcium polymannuronate, Cal-
ginate, E404, KALTOSTAT®); carbomer (also known as 
ACRITAMER®, acrylic acid polymer, CARBO POL®, car-
30 boxy polymethylene, polyacrylic acid, carboxyvinyl poly-
mer, PEMULEN®, CARBOPOL® Ultrez); carboxymethyl-
cellulose calcium (also known as calcium 
carboxymethylcellulose, calcium CMC, ECG 505, NYM-
CEL® ZSC); carboxymethylcellulose sodium (also known as 
35 AKUCELL®, AQUASORB®, BLANOSE®, cellulose gum; 
CMC sodium); cellulose acetate phthalate (also known as 
acetyl phthalyl cellulose, AQUACOAT® cPD, CAP, cella-
cephate, cellulose acetate benzene-! ,2-dicarboxylate, cellu-
lose acetate hydrogen 1 ,2-benzenedicarboxylate, cellulose 
40 acetate hydrogen phthalate, cellulose acetate monophthalate, 
cellulose acetophthalate, cellulose acetylphthalate ); Cerato-
nia (also known as Algaroba, carob bean gum, carob flour, 
ceratonia gum, ceratonia siliqua, ceratonia siliqua gum, 
The ingredients that may be used in embodiments of the 45 
formulation are as follows: 
Cheshire gum, E410, gomme de caroube, locust bean gum, 
Meyprofleur, St. John's bread); croscarmellose sodium (also 
known as AC-DI-SOL™ crosslinked carboxymethylcellu-
Analgesic/anesthetic agents, also termed active agents, 
include benzocaine, lidocaine, novocaine, procaine, buta-
laine, dyclonine, prilocaine, tetracaine, butamben (butyl 
4-aminobenzoate ), cocaine, fidocaine, dibucaine, oxybup-
rocaine, pramoxine, proparacaine, proxymetacaine, ame-
thocaine, cholorbutanol, ambroxol HCl, hexylresorcinol, 
amylmetacresol dichlorobenzylalcohol, dichlorobenzene, 
benzyl alcohol. Combinations of anesthetics include EMLA 
(eutectic mixture oflocal anesthetics) which is a combination 
of lidocaine and prilocaine; TAC which is a combination of 
tetracaine, adrenaline/epinephrine and cocaine; LET which is 
a combination of lidocaine, adrenaline/epinephrine and tet-
racame. 
A wax or mixture of waxes capable of serving as a matrix 
and maintaining its integrity after incorporation of all active 
ingredients and excipients, including after application in the 
mouth, may be used. Thus, any wax or combination of com-
mercially available natural or synthetic waxes and including 
but not limited to the following may be used: anionic emul-
sifying wax, bleached wax, carnauba wax, cetyl esters wax, 
hard wax, microcrystalline wax, nonionic emulsifying wax, 
lose sodium, EXPLOCEL™, modified cellulose gum, NYM-
CEL® ZSX, PHARMACEL® XL, PRIMELLOSE®, 
SOLUTAB®, VIVASOL®); crospovidone (also known as 
so crosslinked povidone, E1202, KOLLIDON® CL, KOLLI-
DON® CL-M, POLYPLASDONE® XL, POLYPLAS-
DONE® XL-10, polyvinylpolypyrrolidone, PVPP, 1-vinyl-
2-pyrrolidinone homopolymer); gelatin (also known as 
BYCO™, CRYOGEL®, gelatin, INSTAGEL™, SOLU-
55 GEL™); glyceryl monooleate (also known as ALDO® MO, 
ATLAS™ G-695, CAPMUL® GMO, glycerol-1-oleate, 
glyceryl mono-oleate, KESSCO™ GMO, Ligalub, mono-
lein, MONOMULS® 90-018, mono-olein, a-mono-olein 
glycerol, PECEOL®, PRIOLUBE® 1408, STEPAN® GMO, 
60 TEGIN®); guar gum (also known as E412, GALACTO-
SOL™, guar flour, jaguar gum, Meyprogat, MEYPRO-
DOR™, Meyprofin); hectorite (also known as Hector clay, 
HECTABRITE® AW, HECTABRITE® DP, Ghassoulite, 
LAPONITE®, SHCa-1, Strese & Hofmarm's Hectorite); 
65 hydroxyethyl cellulose (also known as CELLOSIZE® HEC, 
cellulose hydroxyethyl ether, cellulose hydroxyethylate, eth-
ylhydroxy cellulose, ethylose, HEC, HE cellulose, 2-hy-
US 9,387,190 B2 
7 
droxyethyl cellulose ether, hydroxyethyl ether cellulose, 
hydroxyethyl starch, hyetellose, NATROSOL®, oxycellu-
lose, Tylose PHA); hypromellose (also known as 
BENECEL® MHPC, E464, hydroxypropyl methylcellulose, 
HPMC, METHOCEL®, methylcellulose propylene glycol 5 
ether, methyl hydroxypropylcellulose, METOLOSE®, 
TYLOPUR™); hypromellose acetate succinate (also known 
as AQOAT®, AQOAT® AS-HF/HG, AQOAT® AS-LF/LG, 
AQOAT® AS-MF/MG, cellulose 2-hydroxypropyl methyl 
ether acetate succinate, HPMCAS); hypromellose phthalate 10 
(also known as cellulose phthalate hydroxypropyl methyl 
ether, HPMCP, hydroxypropyl methylcellulose benzene-! ,2-
dicarboxylate, 2-hydroxypropyl methylcellulose phthalate, 
methylhydroxypropylcellulose phthalate); kaolin (also 
known as Argilla, bolus alba, China clay, E559, kaolinite, 15 
Lion, porcelain clay, Sim 90, weisserton, white bole); mag-
nesium aluminum silicate (also known as aluminosilicic acid 
magnesium salt, aluminum magnesium silicate, Carrisorb, 
GELSORB™ MAGNABRITE®, magnesium aluminosili-
cate, magnesium aluminum silicate colloidal, magnesium 20 
aluminum silicate complex colloidal, NEUSILIN®, Pharm-
sorb, silicic acid aluminum magnesium salt, Veegum); meth-
ylcellulose (also known as BENECEL®, CULMINAL® 
MC, E461, METHOCEL®, METOLOSE®); polacrilin 
potassium (also known as AMBERLITE™ IRP-88, meth- 25 
acrylic acid polymer with divinylbenzene potassium salt, 
polacrilinum kalii); polycarbophil (also known as 
NOVEON® AA-1); polyethylene oxide (also known as 
POLYOX®, polyoxirane, polyoxyethylene); polymethacry-
lates (also known as ACRYL-EZE®, ACRYL-EZE® MP, 30 
EASTACRYL® 30D, EUDRAGIT®, KOLLICOAT® MAE 
30 D, KOLLICOAT® MAE 30 DP, polymeric methacrylates; 
USP/NF non-proprietary names are Armnonio methacrylate 
copolymer, methacrylic acid copolymer, methacrylic acid 
copolymer dispersion; saponite (also known as Afrodit, alu- 35 
minum-saponite, auxite, cathkinite, ferroan saponite, grif-
fithite, licianite, lucianite); sodium starch glycolate (also 
known as carboxymethyl starch sodium salt, EXPLOSOL®, 
EXPLOTAB®, GLYCOLYS®, PRIMOJEL®, starch car-
boxymethyl ether sodium salt, TABLO™, VIVASTAR® P); 40 
starch (also known as Amido, amidon, amilo, amylum, 
AYTEX® P, C*PHARMGEL®, FLUFTEX™ W, INSTANT 
PURE-COTE®, MELOJEL®, Meritena, PAYGEL® 55, 
PERFECTAMYL® D6PH, PURE-BIND®, PURE-COTE®, 
PURE-DENT®, PURE-GEL®, PURE-SET®, Purity 21, 45 
Purity 826, Tablet White); tragacanth (also known as Alga-
mba, carob bean gum, carob flour, ceratonia gum, ceratonia 
siliqua, ceratonia siliqua gum, Cheshire gum, E41 0, gomme 
de caroube, locust bean gum, Meyprofleur, St. John's bread); 
xanthan gum (also known as corn sugar gum, E415, 50 
KELTROL®, polysaccharide B-1459, RHODIGEL®, VAN-
ZAN® NF, XANTURAL®); D-a-tocopherol (Vitamin E) 
(also known as COPHEROL® F1300, ( )-3,4-dihydro-2,5,7, 
8-tetramethyl-2-( 4,8, 12-trimethyltridecyl)-2H -1-benzopy-
ran-6-ol; E307, EASTMAN® Vitamin E TPGS, synthetic 55 
alpha tocopherol, all-rac-atocopherol, dl-a-tocopherol, 5,7,8-
trimethyltocol); benzalkonium chloride (also known as alky-
lbenzyldimethylammonium chloride, alkyl dimethyl benzyl 
ammonium chloride, BKC, HYAMINE® 3500, Pentonium, 
ZEPHIRAN®); cetostearyl alcohol (also known as cetearyl 60 
alcohol, CRODACOL™ CS90, LANETTE® 0, TEGO® 
Alkanol1618, Tego Alkanol6855); cetrimide (also known as 
BROMAT™, Cetab, CETAVLON®, Cetraol, Lissolamine V, 
Mica!, MorpanCHSA, Morphans, Quammonium, Suticide); 
cetylpyridinium chloride (also known as C16-alkylpyri- 65 
dinium chloride, CEPACOL®, Cepacol chloride, Cetamiun, 
cetyl pyridium chloride, Dobendan, hexadecylpyridinium 
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chloride, 1-hexadecylpyridinium chloride, Medilave, Prista-
cin; Pyrisept); diethanolamine (also known as bis(hydroxy-
ethyl)amine, DEA, diethylolamine, 2,20-dihydroxydiethy-
lamine, diolamine, 2,20-iminodiethanol); docusate sodium 
(also known as bis(2-ethylhexyl) sodium sulfosuccinate, dio-
ctyl sodium sulfosuccinate, DSS, sodium dioctyl sulfosucci-
nate, sulfo-butanedioic acid 1 ,4-bis(2-ethylhexyl) ester 
sodium salt); glyceryl monostearate (also known as CAP-
MDL® GMS-50, CUTINA® GMS, 2,3-dihydroxypropyl 
octadecanoate, glycerine mono stearate, glycerin mono stear-
ate, glycerol monostearate, glycerol stearate, glyceryl stear-
ate, GMS, IMWITOR® 191, IMWITOR® 900, KESSCO™ 
GMS, Lipo GMS 410, Lipo GMS 450, Lipo GMS 600, 
monoester with 1,2,3-propanetriol, monostearin, MYVA-
PLEX™ 600P, MYVATEX™, 1,2,3-propanetriol octade-
canoate, Protachem GMS-450, Rita GMS, stearic acid 
monoester with glycerol, stearic mono glyceride, STEPAN® 
GMS, TEGIN®, TEGIN® 503, TEGIN® 515, TEGIN® 
4100, TEGIN® M, UNIMATE™ GMS); lauric acid (also 
known as C-1297, dodecanoic acid, dodecoic acid, duode-
cylic acid, n-dodecanoic acid, HYDROFOL™ acid 1255, 
HYDROFOL™ acid 1295, HYSTRENE® 9512, laurostearic 
acid, Neo-fat 12, Neo-fat 12-43, NINOL®AA62Extra, 1-un-
decanecarboxylic acid, vulvic acid, Wecoline 1295); lecithin 
(also known as E322, egg lecithin, LSC 5050, LSC 6040, 
mixed soybean phosphatides, ovolecithin, PHOSAL® 53 
MCT, PHOSPHOLIPON® 100 H, soybean lecithin, soybean 
phospholipids, Sternpur, vegetable lecithin); Macrogol 15 
hydroxystearate (also known as 12-hydroxyoctadecanoic 
acid polymer with alpha-hydro-hydroxypoly( oxy-1 ,2-
ethanediyl), polyethylene glycol 660 12-hydroxystearate, 
SOLUTOL® HS 15); medium-chain triglycerides (also 
known as BERGABEST®, caprylic/capric triglyceride, 
CAPTEX® 300, CAPTEX® 355, CRODAMOL™ GTC/C, 
glyceryl tricaprylate/caprate, LABRAFAC™ CC, MCT oil, 
MIGLYOL® 810, MIGLYOL® 812, MYRITOL®, 
NEOBEE® M5, Nesatol, oleum neutral, oleum vegetable 
tenue, thin vegetable oil, Waglinol 3/9280); monoethanola-
mine (also known as ll.-aminoethyl alcohol, colamine, ethy-
lolamine, ~-hydroxyethylamine, 2-hydroxyethylamine ); 
myristic acid and its salts (also known as EDENOR® C14 
98-100, n-tetradecanoic acid, 1-tridecanecarboxylic acid); 
palmitic acid and its salts (also known as cetylic acid, EDE-
NOR® C16 98-100, EMERSOL® 140, EMERSOL® 143, 
n-hexadecoic acid, hexadecylic acid, HYDROFOL™, HYS-
TRENE® 9016, INDUSTRENE® 4516, 1-pentadecanecar-
boxylic acid, hexadecanoic acid sodium salt, palmitic acid 
sodium salt, sodium hexadecanoate, myricyl palmitate); 
Poloxamer (also known as Lutrol, MONOLAN™, PLU-
RONIC®, poloxalkol, polyethylene-propylene glycol 
copolymer, polyoxyethylene-polyoxypropylene copolymer, 
Supronic, SYNPERONIC®); polyoxyethylene alkyl ethers 
(synonyms applicable to polyoxyethylene alkyl ethers are 
BRIJ®, CREMOPHOR® A, CYCLOGOL™ 1000, 
EMPILAN® KB, EMPILAN® KM, EMULGENT®, 
ETHYLAN™ C, macrogol ethers, MARLOWET®, PLU-
RAFAC™, PROCOL®, Ritoleth, Ritox, Texofor A, Volpo); 
polyoxyethylene castor oil derivatives (also known asACCO-
NON®, ARLATONE®, CREMOPHOR®, ETOCAS™, 
EUMULGIN®, JEECHEM®, LIPOCOL®, MAPEG®, 
MARLOWET®, NIKKOL®, Protachem, SIMULSOL™; 
polyoxyethylene sorbitan fatty acid esters (also known as 
Tweens, polysorbates of varying molecular weight); poly-
oxyethylene stearates (also known as ethoxylated fatty acid 
esters, macrogol stearates, MARLOSOL™, PEG fatty acid 
esters, PEG stearates, polyethylene glycol stearates, poly 
( oxy-1 ,2-ethanediyl) a-hydro-o-hydroxyoctadecanoate, 
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polyoxyethylene glycol stearates); potassium sorbate (also 
known as E202, 2,4-hexadienoic acid (E,E)-potassium salt, 
potassium (E,E)-hexa-2,4-dienoate, potassium (E,E)-sor-
bate; sorbic acid potassium salt); sodium Iaury! sulfate (also 
known as dodecyl sodium sulfate, ELFAN® 240, sodium 
dodecyl sulfate, sodium laurilsulfate, sodium monododecyl 
sulf~te, sodium monolauryl sulfate, TEXAPON® K12P); 
sorb1tan esters (sorbitan fatty acid esters) (also known as 
Spans); stearic acid and its salts (also known as cetylacetic 
acid, crodacid, E570, EDENOR®, EMERSOL®, HYS- 10 
TRENE®, INDUSTRENE®, KORTACID™ 1895, Pearl 
Steric, PRISTERENE®, stereophonic acid, Tegostearic); tri-
et~anolamine (also known as TEA, Tealan, triethylolamine, 
t~1hydroxytriethylamine, tris (hydroxyethyl)amine ); triethyl 
c1trate (also known as citric acid ethyl ester, CITRO FLEX® 15 
2, CITROFOL™ AI, E1505, HYDAGEN® CAT, TEC). 
The embodiments shown and described in the specification 
are only specific embodiments of the inventor who is skilled 
in the art and thus are not limiting in any way. Various 
changes, modifications, or alterations may be made or 20 
resorted to without departing from the spirit of the invention 
or t~~ scope ~fthe following claims. As only two examples, 
additiOnal act1ves may be incorporated into the formulation to 
provide additional medicinal effects, and/or the formulation 
may be provided in another type of carrier for self-application 25 
to the orthodontic bracket. 
What is claimed is: 
1. A method of alleviating orthodontic discomfort in a 
patient in need thereof, the method comprising applying a 
pharmaceutically acceptable composition of a wax, from 30 
0.01% to less than 15% of an analgesic/anesthetic agent, and 
up to 30% xanthum gum to provide to the patient under 
conditions to alleviate orthodontic discomfort for at least 
eight hours and up to 24 hours after the application. 
10 
microcrystalline wax, 0%-10% glyceryl mono stearate, 
0%-30% heavy mineral oil, 0%-30% PEG 1500, 0.01%-
14.99% analgesic/anesthetic agent, 0%-10% Tween 80, and 
0.1 %-30% xanthum gum, the composition applied to an orth-
odontic bracket or brace of the orthodontic patient under 
conditions to alleviate orthodontic discomfort. 
5. The method of claim 1, the composition comprising 
from 50%-99% microcrystalline wax. 
6. The method of claim 1, the composition comprising 83% 
microcrystalline wax. 
7. The method of claim 1, the composition further com-
prising up to 10% glyceryl monostearate. 
8. The method of claim 1, the composition further com-
prising up to 30% heavy mineral oil. 
9. The method of claim 1, the composition further com-
prising up to 30% PEG 1500. 
10. The method of claim 1, the composition further com-
prising up to 10% Tween 80. 
11. The method of claim 1, the composition comprising 5% 
analgesic/anesthetic agent. 
12. The method of claim 1, wherein the analgesic/anes-
thetic agent is benzocaine. 
13. The method of claim 1, wherein the applying step 
applies the composition to an orthodontic bracket or brace 
affixed to at least one tooth of a patient. 
14. The method of claim 1, wherein the applying step 
applies the composition to an oral mucosal surface in a 
patient. 
15. A extended release pharmaceutically acceptable com-
position comprising microcrystalline wax, glyceryl 
monostearate, heavy mineral oil, PEG 1500, Tween 80, less 
than 15.0% of an analgesic/anesthetic agent, and up to 30% 
xanthum gum, the composition having an in-vitro release of 
the analgesic/anesthetic agent of about 28% to about 56% 
over eight hours. 
16. The composition of claim 15, the composition com-
prising from 50%-99% microcrystalline wax. 
2. A method of alleviating orthodontic discomfort in a 35 
patient in need thereof, the method comprising applying a 
pharmaceutically acceptable composition of wax, glyceryl 
monostearate, heavy mineral oil, PEG 1500, Tween 80, from 
0.01% to less than 15% of an analgesic/anesthetic agent, and 
up to 30% xanthum gum. 
17. The composition of claim 15, the composition further 
40 comprising up to 10% glyceryl monostearate. 
18. The composition of claim 15, the composition further 
comprising up to 30% heavy mineral oil. 
3. A method of alleviating orthodontic discomfort in a 
patient in need thereof, the method comprising applying a 
pharmaceutically acceptable composition of83% microcrys-
talline wax, 2.7% glyceryl monostearate, 1.0% heavy mineral 
oil, 5% PEG 1500, 5% analgesic/anesthetic agent, 0.3% 45 
Tween 80, and 3% xanthum gum, the composition applied to 
an oral mucosal surface of the orthodontic patient under con-
ditions to alleviate the orthodontic discomfort. 
4. A method of alleviating orthodontic discomfort in a 
patient in need thereof, the method comprising applying a so 
pharmaceutically acceptable composition of 50%-99% 
19. The composition of claim 15, the composition further 
comprising up to 30% PEG 1500. 
20. The composition of claim 15, the composition further 
comprising up to 10% Tween 80. 
21. The composition of claim 15, the composition com-
prising 5% analgesic/anesthetic agent. 
22. The composition of claim 15, wherein the analgesic/ 
anesthetic agent is benzocaine. 
* * * * * 
